Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

Abstract

Adropin is a peptide hormone, which plays a role in energy homeostasis and controls glucose and fatty acid metabolism. Its levels correlate with changes in carbohydratelipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. Both metabolic pathways and adropin are regulated by the circadian clocks. Here, we review the roles of the autonomic nervous system and circadian rhythms in regulating metabolic pathways and energy homeostasis. The beneficial effects of chronotherapy in various systems are discussed. We suggest a potential role for adropin as a mediator of the metabolic system-autonomic nervous system axis. We discuss the possibility of establishing an individualized adropin and circadian rhythm-based platform for implementing chronotherapy, and variability signatures for improving the efficacy of adropin-based therapies are discussed. K E Y W O R D S adropin, autonomic nervous system, chronobiology, metabolic syndrome 1 | INTRODUCTION Metabolic syndrome (MetS) is a cluster of metabolic and cardiovascular complications, which increase the risk of cardiovascular diseases (CVD) and type 2 diabetes (T2D). 1 The pathogenesis of MetS involves multiple factors, including the autonomic nervous system (ANS) and the circadian rhythm. 2 Recently, MetS was also shown to increase the risk and mortality of cancer, 3 with which it shares many risk factors including age, genetic factors, obesity, physical inactivity, unhealthy diet, alcohol, smoking, endocrine disruptors exposure and air pollution. Recent studies have suggested that several peptide hormones play important roles in the modulation of systemic metabolism and energy homeostasis. Adropin is a product of the energy homeostasis associated (Enho) gene and a peptide hormone that plays a role in the regulation of energy homeostasis and controls glucose and fatty acid metabolism. It was originally described as a secreted peptide, with

Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor

“…Regular fixed regimens for the administration of chronic drugs may not be compatible with physiological variabilities in biology, and this can underlie the loss of response to chronic drugs [ 26 , 28 , 47 , 48 , 49 ]. However, introducing variability into therapeutic regimens can improve the response to drugs [ 26 , 27 , 28 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. Dose escalations, reductions, and intermittent dosing with drug holidays exert clinical benefits while minimizing adverse effects [ 20 , 60 , 61 , 62 , 63 ].…”

“…A prospective trial of patients with inflammatory bowel disease treated with anti-TNFs showed a loss of clinical response in 36% of patients on fixed dosing, compared with only 13% in patients on variable dosing regimens [ 64 ]. Real-world data support the beneficial effects of drug holidays and dose escalation/reduction [ 24 , 28 , 29 , 49 , 50 , 54 , 55 , 56 , 57 , 65 , 66 ]. Introducing variability into biological systems may improve their overall function and correct dysfunctions that underlie diseases [ 26 , 67 ].…”

“…Introducing variability into biological systems may improve their overall function and correct dysfunctions that underlie diseases [ 26 , 67 ]. Both the type and magnitude of variability in a biological system can be personalized by continuously quantifying individualized variability patterns and implementing them into algorithms [ 4 , 27 , 28 , 49 , 50 , 51 , 52 , 54 , 68 ].…”

“…The digital pill supports the use of generics and biosimilars for NCDs by improving their clinical effectiveness. The digital pill overcomes the primary and secondary loss of response and improves adherence to chronic drugs [ 26 , 27 , 42 , 49 , 50 , 51 , 54 , 58 ]. The increase in response rate to chronic medications reduces expenses by saving on the unnecessary admission of patients who are no longer responding to their chronic medications, and the need to introduce patients to newer and, in most cases, more expensive agents.…”

Why scientists, academic institutions, and investors fail in bringing more products to the bedside: the Active Compass model for overcoming the innovation paradox

“…Ignoring this problem is associated with lower effectiveness in many drugs used for chronic conditions, Ilan J Transl Med (2021) 19:55 sometimes in up to 40% of patients, such as those with epilepsy or depression, where many patients develop drug resistance [20,21]. Thus, next-generation translation research is required to provide a way to deal with compensatory responses [22][23][24][25][26][27][28][29][30].…”